GlassScriptPhysician profile
Austin Ruppanner
NPI 1700491735
$3,945.31
in general payments reported to CMS, 2019-2025
29 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $596 · 2022: $1,097 · 2023: $1,064 · 2024: $695 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $521.14 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $395.44 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $364.87 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $337.24 | 2021-2025 | |
| Mylan Specialty L.P. | $335.70 | 2021-2024 | Yupelri |
| Antares Pharma, INC. | $245.27 | 2024-2025 | Xyosted |
| Otsuka America Pharmaceutical, INC. | $206.24 | 2021-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.77 | 2021-2023 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.40 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $164.97 | 2022-2024 | |
| Glaxosmithkline, LLC. | $162.99 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $144.66 | 2021-2023 | Austedo Xr, Austedo |
| Pfizer INC. | $100.44 | 2021-2023 | |
| Amarin Pharma, INC. | $91.39 | 2021 | |
| Idorsia Pharmaceuticals US INC | $72.81 | 2023-2024 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $69.41 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $67.84 | 2022 | |
| Gilead Sciences, INC. | $45.86 | 2023-2024 | Epclusa |
| Dexcom, INC. | $45.00 | 2022-2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $39.64 | 2025 | Korlym |
| Genentech USA, INC. | $23.32 | 2021 | |
| Nevro Corp. | $19.91 | 2023 | Senza |
| Paratek Pharmaceuticals, INC. | $19.17 | 2024 | Nuzyra |
| Pacira Therapeutics, INC. | $17.28 | 2021 | |
| Amgen INC. | $16.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.35 | 2023 | Xarelto |
| Acella Pharmaceuticals, LLC | $13.92 | 2025 | NP Thyroid 60 |
| Shield Therapeutics INC | $13.54 | 2023 | Accrufer |
| Eisai INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Ruppanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.